The factory that had to toss J&J coronavirus vaccines has made 150 million doses. Regulators haven't let any reach the public.

A nurse loads a syringe with a dose of Johnson & Johnson's COVID-19 vaccine on March 9, 2021 in Athens, Ohio. Stephen Zenner / SOPA Images / LightRocket via Getty Images
More
A factory for Emergent BioSolutions has made 150 million Johnson & Johnson vaccine doses.
The cans go unused because the regulators have not certified the factory to distribute the shots.
Last month it was revealed that this facility botched 15 million doses of the COVID-19 vaccine.
You can find more articles on Insider's business page.
A Baltimore factory that botched the production of 15 million doses of the Johnson & Johnson COVID-19 vaccine was unable to distribute any of its doses due to a certification issue, according to the New York Times.
The factory for Emergent BioSolutions, a biotech company known for making anthrax vaccines, has made at least 150 million Johnson & Johnson vaccine doses, none of which have been used, according to The Times.
The manufacturing facility ruined 15 million doses of the Johnson & Johnson vaccine last month when an employee reportedly mixed up the vaccine ingredients.
The error occurred just a month after the vaccine was approved in the US. At that point, the company had announced that it would deliver 100 million doses by the end of June and 1 billion doses by the end of June.
As of April 3, about 3.8 million doses of the J&J vaccine had been administered, according to the Wall Street Journal. In total, approximately 162 million vaccine doses have been administered in the United States between J&J, Moderna, and Pfizer.
The bug did not affect any Johnson & Johnson vaccines that had already been shipped, but it delayed the vaccine's production and shipping schedules for several weeks. The facility should be producing tens of millions of doses of the Johnson & Johnson vaccine by the end of May.
Emergent BioSolutions told Insider that the company's quality control systems "work to detect and isolate batches that for some reason do not meet quality standards."
"Nobody, including Emergent employees, wants to see vaccines that cannot be used," the company said in a statement, adding, "Any allegation that our safety, quality and compliance systems are not working, or that we are Not taking those responsibilities seriously are clearly wrong. "
Emergent Biosolutions also has a history of quality control issues and was once cited by the Food and Drug Administration for a number of issues, including mold and cracked vials, the Associated Press reported.
Around the same time, J&J announced its partnership with Emergent Biosolutions. The company signed a five-year contract, the first two years of which were valued at $ 480 million, according to Emergent Biosolutions.
Read the original article on Business Insider
Mention your own website in this post for Advertisement

Last News

Trump Rips 'Dumb Son Of A Bitch' Mitch McConnell At RNC Donor Event: Report

John Boehner on how history will judge presidents he’s known. Trump: ‘I don’t think very well’

Jennifer Lopez's Latest Instagram Post Is Fueling New Speculation About Her Relationship Status

Kristin Cavallari says sharing custody with ex Jay Cutler has made her a 'better mom': 'When I have them for my week, I am so incredibly present'

Las Vegas pushes to become first to ban ornamental grass

India bans Remdesivir exports as coronavirus rages on; rallies continue